Reimbursed Care Access in Burundi

Currently classified as a strictly controlled substance under international and Burundi national drug‑control frameworks, with no authorized medical use outside of approved clinical research. Burundi is a Party to the 1971 Convention on Psychotropic Substances which requires control of hallucinogens and psychotropic drugs at the national level #. Burundi's penal code and criminal legislation criminalise illicit production, possession and trafficking of controlled drugs and prescribe criminal sanctions (see national penal code drug‑related articles). #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Burundi implements drug control measures consistent with international conventions that cover MDMA and other synthetic entactogens. # #

Esketamine (intranasal) is an approved, regulated medicine for treatment‑resistant depression in several high‑income jurisdictions, but there is no publicly available record of national marketing authorization, reimbursement policy, or routine clinical availability for esketamine in Burundi. International regulatory approvals (for example Spravato in the United States and in the EU) set out controlled distribution and specialist prescribing requirements in those jurisdictions, but those country‑level authorisations do not equate to registration or reimbursement in Burundi. For reference on international approvals and controlled distribution models see Spravato regulatory information. # The absence of an observable national reimbursement or registration pathway for esketamine in Burundi, combined with Burundi’s obligations under international drug conventions and national criminal penalties for illicit drugs, means esketamine would only be accessible in Burundi within an authorised clinical‑research context if and when a sponsor obtains local regulatory approval or ethics approval for trials. #

Ketamine is listed on the WHO Model List of Essential Medicines as an injectable general anaesthetic and is globally recognised as an important, licit medicine for surgical anesthesia and emergency care; this status supports its medical availability in many low‑resource health systems, including countries in East Africa. #.

In Burundi specifically, national health authorities and hospital services (public and private) use standard anaesthetics consistent with WHO guidance; ketamine is therefore the most likely legal route by which the compound appears in clinical practice in Burundi (as an anaesthetic/analgesic). However, there is no publicly available evidence of a national regulatory or health‑insurance reimbursement framework in Burundi that recognises or reimburses ketamine for psychedelic‑assisted psychotherapy or for officially sanctioned psychiatric indications beyond its established anaesthetic/acute care uses. Public reimbursement for novel psychiatric uses (e.g., ketamine infusion clinics, repeat outpatient protocols for depression) typically requires explicit national regulatory guidance, insurance coding and/or public health programme inclusion — none of which are evident in Burundi's publicly available regulatory material. For the medical essential‑medicine position see WHO. For Burundi legal provisions criminalising unauthorized drug distribution and trafficking, see national penal code provisions. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Burundi is party to international psychotropic drug controls that cover naturally occurring and synthetic hallucinogens such as DMT; national penal provisions criminalise illicit possession, production and trafficking. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT, like other powerful tryptamine hallucinogens, falls within the scope of national controls applied pursuant to the 1971 Convention; there is no public evidence of any authorised medical or licenced therapeutic programme for 5‑MeO‑DMT in Burundi. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no indication of an authorised or reimbursed treatment pathway for ibogaine in Burundi; access, if any, would be confined to formally authorised clinical research and would require national approvals. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. While ayahuasca is a botanical brew containing DMT and MAOI‑containing plants, under Burundi law the psychoactive components and preparations containing controlled substances would be subject to the same national controls and penalties for illicit handling. There is no public evidence of legal religious or therapeutic exemptions in Burundi. #

Currently classified as a strictly controlled substance under national and international drug‑control frameworks, with no authorized medical use outside of approved clinical research. Mescaline (synthetic or derived from cacti) is covered by psychotropic control regimes; no legal therapeutic or reimbursement pathway for mescaline exists in Burundi based on available public sources. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The family of substituted phenethylamines (including 2C‑series compounds) is subject to control under international and national psychotropic substance regimes; no authorised medical use or reimbursement pathway is documented for Burundi. #